ATE299369T1 - Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine - Google Patents

Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine

Info

Publication number
ATE299369T1
ATE299369T1 AT00953996T AT00953996T ATE299369T1 AT E299369 T1 ATE299369 T1 AT E299369T1 AT 00953996 T AT00953996 T AT 00953996T AT 00953996 T AT00953996 T AT 00953996T AT E299369 T1 ATE299369 T1 AT E299369T1
Authority
AT
Austria
Prior art keywords
cyclobenzaprine
compositions
treating
sleep disorders
low doses
Prior art date
Application number
AT00953996T
Other languages
English (en)
Inventor
Iredell W Iglehart Iii
Original Assignee
Vela Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vela Pharmaceuticals Inc filed Critical Vela Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE299369T1 publication Critical patent/ATE299369T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00953996T 1999-08-13 2000-08-11 Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine ATE299369T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14888199P 1999-08-13 1999-08-13
PCT/US2000/022082 WO2001012175A1 (en) 1999-08-13 2000-08-11 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine

Publications (1)

Publication Number Publication Date
ATE299369T1 true ATE299369T1 (de) 2005-07-15

Family

ID=22527835

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00953996T ATE299369T1 (de) 1999-08-13 2000-08-11 Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine

Country Status (18)

Country Link
US (3) US6395788B1 (de)
EP (1) EP1202722B1 (de)
JP (1) JP2003506484A (de)
AR (1) AR025110A1 (de)
AT (1) ATE299369T1 (de)
AU (1) AU6635400A (de)
BR (1) BR0013017A (de)
CA (1) CA2380432A1 (de)
DE (1) DE60021266T2 (de)
ES (2) ES2245944T3 (de)
GB (1) GB2368522A (de)
HK (2) HK1047883A1 (de)
IL (1) IL147777A0 (de)
MX (1) MXPA02001569A (de)
NZ (1) NZ516749A (de)
PT (1) PT1202722E (de)
WO (1) WO2001012175A1 (de)
ZA (2) ZA200200619B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000048581A2 (en) * 1999-02-18 2000-08-24 Novartis Ag Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
GB0128674D0 (en) * 2001-11-30 2002-01-23 Boots Co Plc Treatment of sleep disorders and the like
GB0312425D0 (en) * 2003-05-30 2003-07-09 Boots Co Plc Use of a compound in the treatment of sleep disorders and the like,in providing refreshedness on waking and a method for the treatment of grogginess therewith
JP4578083B2 (ja) * 2003-09-30 2010-11-10 小林製薬株式会社 催眠剤組成物
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20070087055A1 (en) * 2005-10-14 2007-04-19 David Jan Directly compressible extended release alprazolam formulation
EP2998288B1 (de) 2005-12-01 2022-08-24 ACADIA Pharmaceuticals Inc. Substituierte phenethylamine mit serotoninergischer und/oder norepinephrinergischer aktivität
WO2007098202A2 (en) * 2006-02-16 2007-08-30 Imthera Medical, Inc. An rfid based apparatus, system, and method for therapeutic treatment of a patient
US20100179215A1 (en) * 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
CA2680912C (en) 2007-03-15 2017-11-14 Auspex Pharmaceuticals, Inc. Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
JP2011500143A (ja) 2007-10-09 2011-01-06 イムセラ・メディカル・インコーポレーテッド 選択的刺激のための装置、システム、及び方法
EP2313091A4 (de) * 2008-07-14 2012-04-04 Univ Kingston Pharmazeutische zusammensetzungen mit ret-hemmern und verfahren zur behandlung von krebs
WO2010042404A1 (en) 2008-10-09 2010-04-15 Imthera Medical, Inc. Method of stimulating a hypoglossal nerve for controlling the position of a patient's tongue
US9498440B2 (en) 2009-05-22 2016-11-22 Inventia Healthcare Private Limited Extended release pharmaceutical compositions
AU2010318651A1 (en) 2009-11-10 2012-05-03 Imthera Medical, Inc. System for stimulating a hypoglossal nerve for controlling the position of a patient's tongue
PT2501234T (pt) 2009-11-20 2017-12-13 Tonix Pharma Holdings Ltd Métodos e composições para o tratamento de sintomas associados com distúrbios de stress pós-traumático utilizando ciclobenzaprina
US20110319389A1 (en) * 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) * 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
ITMI20110558A1 (it) * 2011-04-06 2012-10-07 Campiglio Consulting Srl Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale
WO2013168004A2 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
SI2861223T1 (sl) 2012-06-15 2023-01-31 Tonix Pharma Holdings Limited Sestavki in postopki za transmukozalno absorpcijo
MY196014A (en) 2013-03-15 2023-03-06 Tonix Pharmaceuticals Inc Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride
SG10201902203VA (en) 2014-09-18 2019-04-29 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
JP2020526592A (ja) 2017-07-13 2020-08-31 トニックス ファーマシューティカルズ ホールディング コーポレーション シクロベンザプリン類似体及びアミトリプチレン類似体
BR112020011345A2 (pt) 2017-12-11 2020-11-17 Tonix Pharma Holdings Limited tratamento com ciclobenzaprina para agitação, psicose e declínio cognitivo na demência e condições neurodegenerativas
WO2019245975A1 (en) 2018-06-17 2019-12-26 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
EP3840738A1 (de) 2018-08-20 2021-06-30 Tonix Pharma Holdings Limited Verfahren zur behandlung von akuter belastungsstörung und posttraumatischer belastungsstörung
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US12616702B2 (en) 2019-12-03 2026-05-05 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
JP7780447B2 (ja) * 2020-04-08 2025-12-04 トニックス ファーマシューティカルズ ホールディング コーポレイション 性機能障害のシクロベンザプリン処置
MX2023005899A (es) 2020-11-20 2023-08-16 TONIX Pharmaceuticals Holding Corp Tratamiento con ciclobenzaprina para el trastorno por consumo de alcohol.
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same
US12565478B1 (en) 2025-01-21 2026-03-03 Axsome Therapeutics, Inc. (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1339636A (en) * 1917-02-23 1920-05-11 Tulloch Thomas Gregorie Fluid-tight joint for steam-pipes and the like
GB859187A (en) 1958-11-25 1961-01-18 United States Borax Chem Method for preparing substituted tris amino boranes
CA958643A (en) 1970-07-07 1974-12-03 Frosst (Charles E.) And Co. Pharmaceutical compositions containing cyclobenzaprine
FR2121529A1 (en) 1971-01-05 1972-08-25 Merck & Co Inc Compsns contg cyclobenzaprine and indomethacin - chlordiazepoxide, phenylbutazone oxyphenbutazone or corticosteroid
AR025111A1 (es) * 1999-08-13 2002-11-06 Janus Pharmaceuticals Inc Metodos y composiciones para tratar trastornos de ansiedad generalizada

Also Published As

Publication number Publication date
GB0202908D0 (en) 2002-03-27
ES2192156A1 (es) 2003-09-16
US20010046988A1 (en) 2001-11-29
GB2368522A (en) 2002-05-08
ES2192156B1 (es) 2005-02-16
ZA200200852B (en) 2003-07-30
DE60021266D1 (de) 2005-08-18
WO2001012175A8 (en) 2001-05-10
ZA200200619B (en) 2003-04-23
MXPA02001569A (es) 2002-07-02
JP2003506484A (ja) 2003-02-18
AR025110A1 (es) 2002-11-06
US20040029869A1 (en) 2004-02-12
EP1202722B1 (de) 2005-07-13
US6541523B2 (en) 2003-04-01
GB2368522A8 (en) 2002-06-13
HK1047691B (en) 2006-05-12
WO2001012175A1 (en) 2001-02-22
HK1047691A1 (en) 2003-03-07
BR0013017A (pt) 2002-04-16
DE60021266T2 (de) 2006-05-24
NZ516749A (en) 2004-03-26
EP1202722A1 (de) 2002-05-08
PT1202722E (pt) 2005-11-30
AU6635400A (en) 2001-03-13
US6395788B1 (en) 2002-05-28
CA2380432A1 (en) 2001-02-22
HK1047883A1 (zh) 2003-03-14
ES2245944T3 (es) 2006-02-01
IL147777A0 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
DE60021266D1 (de) Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
ATE265857T1 (de) Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie
EP1274444A4 (de) Arzneistoffe zur behandlung psychiatrischer oder abusus-bedingter störungen
ATE291438T1 (de) Pharmazeutische zusammensetzung zur behandlung von akutem schmerz, chronischem schmerz und/oder neuropathischem schmerz und migräne
ATE446097T1 (de) Verwendung von uridin in kombination mit cholin zur behandlung von gedächtnisstörungen
DE60127277D1 (de) Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
DE122006000035I1 (de) D2-Agonist enthaltendes transdermales Therapeutisches System zur Behandlung des Parkinson-syndroms und Berfahren zu seiner Herstellung
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE69726245D1 (de) Befeuchtungsgerät zur Behandlung von Atemstillstand im Schlaf
DE59601624D1 (de) Verwendung von 2-amino-4-(4-fluorbenzylamino)-1-ethoxycarbonylaminobenzen zur prophylaxe und behandlung der folgen der akuten und chronischen zerebralen minderdurchblutung sowie neurodegenerativer erkrankungen
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
DE60134009D1 (de) Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
EP1043983A4 (de) Tetracycline und/oder tetracyclinderivate zur behandlung und prophylaxe von cerebrovascularen krankheiten des nervensystems
PL357674A1 (pl) Kompozycje i sposoby leczenia zaburzeń związanychz hiperlipidemią
DE69825279D1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
ATE237341T1 (de) Zusammensetzung zur vorbeugung und/oder behandlung von kreislaufstörungen, enthaltend l- carnitin derivate und ginkgo biloba extrakte
DE69910202D1 (de) EGR-1 zur Herstellung eines Medikamentes zur Behandlung von Wunden
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE69925578D1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE234617T1 (de) Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1202722

Country of ref document: EP

EEIH Change in the person of patent owner
EEIH Change in the person of patent owner